REDEFINE 1 tested a cagrilintide–semaglutide combination alongside component and placebo groups. It is not a trial of cagrilintide alone or of a separately prepared commercial blend. Primary trial
Trial snapshot
The 68-week phase 3a trial randomized 3,417 adults without diabetes and with obesity or qualifying overweight. The treatment-policy estimate of weight change was −20.4% with the combination and −3.0% with placebo. Gastrointestinal adverse events were more frequent with the combination. Semaglutide-only and cagrilintide-only groups were also included. Novo Nordisk funded the trial; registration is NCT05567796. Primary trial
Our appraisal: an estimand is part of the result
An effect estimate needs its analysis question attached. A treatment-policy estimate should not be silently mixed with an estimate asking what would happen under uninterrupted treatment. Missing data and treatment changes need the methods' stated handling, not an assumption that all participants followed the same course.
The four-arm design also does not make every displayed contrast interchangeable. A combination-versus-placebo result does not identify either component's independent contribution. Component comparisons should be extracted separately with their own uncertainty and prespecified testing context.
For release review, inspect participant flow, analysis assumptions, endpoint hierarchy, component comparisons, and complete adverse-event reporting. No numerical result here establishes the effect of an unverified mixture made outside the trial.
Frequently asked questions
Did participants have type 2 diabetes?
This trial enrolled adults without diabetes.
Were there component-only groups?
Yes, as well as combination and placebo groups.
Is the reported estimate an individual prediction?
No. It summarizes a study population under an analysis framework.
Can component results be inferred from the placebo contrast?
No. They require their own comparisons.
Were gastrointestinal events absent?
No. They were more frequent with the combination.
Does this establish current approval status?
No. This page appraises a historical report, not current labeling.
What source scope is claimed?
The primary indexed abstract. Full report, supplement, registry, and publication-history checks remain pending.